Spearheading collaborative research and innovation in hematology, driving impactful therapeutic advancements as Chief Medical Officer. Expertise spans drug development, science-driven investment, clinical trials, and strategic analysis, reinforced through board-level contributions and a proven commitment to transforming patient outcomes.
Venture investments by identifying and evaluating new breakthrough science in collaboration with multiple life sciences funds and partners.

Previous leadership roles at Deciphera Pharmaceuticals, Kyowa Kirin, IQVIA, Sanofi and Amgen emphasized drug strategy and clinical development. Extensive experience in R&D and clinical research reflects a career mission to align scientific breakthroughs with strategic objectives. Dedicated to fostering innovation and shaping the future of oncology and hematology therapeutics.